Veru reports third quarter fiscal 2022 financial results; progresses sabizabulin treatment for covid-19 towards regulatory decisions in key territories

-- sabizabulin for covid-19 emergency use authorization application submitted to u.s. fda in june 2022-- --the uk's medicines and healthcare products regulatory agency informed the company that its sabizabulin marketing authorization application will receive expedited review--
VERU Ratings Summary
VERU Quant Ranking